Skip to main content
Premium Trial:

Request an Annual Quote

Santaris Presents Phase IIa Data on microRNA-Targeting HCV Drug

Premium

Santaris Pharma this week announced additional data from its phase IIa trial of miravirsen, its locked nucleic acid-based miR-122 inhibitor for the treatment of hepatitis C.

In the trial, treatment-naive HCV patients received weekly doses of the drug at either 3 mg/kg, 5 mg/kg, or 7 mg/kg levels over 29 days via subcutaneous injection.

Of the nine patients treated at the highest dose, four became HCV RNA undetectable during the study, Santaris said. Additionally, the therapy resulted in a mean reduction of 2 to 3 logs from baseline RNA levels, which was maintained for more than four weeks after the end of treatment.

"These data ... show that longer duration of miravirsen monotherapy has the potential to produce sustained virological responses,” Harry Janssen, lead investigator of the study, said in a statement.

The data were presented at the this month's meeting of the American Association for the Study of Liver Diseases. Additional data were presented ahead of the meeting last month (GSN 10/6/2011).

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.